NeoImmuneTech, Inc. (KOSDAQ:950220)
South Korea · Delayed Price · Currency is KRW 2,590.00
+85.00 (3.39%)
Sep 1, 2026, 3:30 PM KST
NeoImmuneTech Revenue
NeoImmuneTech had revenue of 1.17B KRW in the quarter ending June 30, 2026, with 4,559.27% growth. This brings the company's revenue in the last twelve months to 1.76B, up 744.13% year-over-year. In the year 2025, NeoImmuneTech had annual revenue of 94.82M, down -44.35%.
Revenue (ttm)
1.76B
Revenue Growth
+744.13%
P/S Ratio
145.49
Revenue / Employee
33.85M
Employees
52
Market Cap
256.07B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 94.82M | -75.56M | -44.35% |
| Dec 31, 2024 | 170.38M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Corp. | 2.49T |
| Bioneer | 338.01B |
| GC Cell | 162.00B |
| MEDIPOST | 74.84B |
| HLB Therapeutics | 64.45B |
| GC Genome | 32.64B |
| SillaJen | 10.92B |
| Anterogen.Co.,Ltd. | 8.37B |